Citadel Advisors
ELTX icon

Citadel Advisors’s Elicio Therapeutics ELTX Stock Holding History

Citadel Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$525K Buy
134,200
+88,900
+196% +$893K ﹤0.01% 9748
2026
Q1 		$484K Buy
45,300
+10,100
+29% +$97.5K ﹤0.01% 9392
2025
Q4 		$280K Buy
35,200
+14,200
+68% +$129K ﹤0.01% 10285
2025
Q3 		$230K Buy
+21,000
New +$213K ﹤0.01% 10945

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Citadel Advisors's ELTX Position: Q2 2026 in Review

Citadel Advisors sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 15,978 shares — an estimated $160K sold.

Citadel Advisors first reported a position in ELTX in Q1 2021 and held it in 8 quarters. The position peaked at $631K in Q1 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Citadel Advisors reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 15,978 Elicio Therapeutics shares in Q2 2026, an estimated $160K.
  • Citadel Advisors first reported a position in Elicio Therapeutics in Q1 2021 and held it in 8 quarters.
  • Citadel Advisors's Elicio Therapeutics position peaked at $631K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.